Omeros Q3 Yartemlea sales climb 30%, but derivative charge drives $57.4 million loss
SEC · · AI-summarised by FinFlash
Omeros reported third-quarter net product revenue of $35.9 million, up from $28.5 million in the second quarter, as gross sales of its drug Yartemlea rose about 30% to $41.8 million. A non-cash $62.0 million mark-to-market loss on a derivative tied to its 2029 notes produced a GAAP net loss of $57.4 million, or $0.79 a share, while adjusted profit was $4.7 million. Cash stood at $95.3 million after positive operating cash flow of Accelerating Yartemlea uptake supports the commercial story, though a negative EU opinion and rising gross-to-net deductions are risks; watch 2027 reimbursement changes. Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.So What?
Understand the context